Trial Profile

Phase I trial of AmpliPhage-002 in patients with Staphylococcus aureus topical and wound infections.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AP SA01 (Primary)
Indications Skin and soft tissue infections; Staphylococcal infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

09 Jan 2015 New trial record
06 Jan 2015 Instead of initiating this trial, AmpliPhi Biosciences Corporation may initiate a proof-of-concept trial of AmpliPhage 002 for nasal decolonisation of multidrug-resistant Staphylococcus aureus, according to a company media release.
06 Jan 2015 After completion of preclinical studies in 2015, this trial is expected to be initiated at the Walter Reed Institute of Research in the second half of 2015, according to an AmpliPhi Biosciences Corporation media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com